DCGI’s nod to AstraZeneca to import, market Selumetinib Capsules

Download all types of Clinical Trial Forms

48
DCGI CDSCO

Last Updated on September 29, 2021 by The Health Master

NEW DELHI: Drug firm AstraZeneca Pharma India on Sunday said it has received import and market permission from the Indian drug regulator Drugs Controller General India (DCGI) for Selumetinib capsules.

The company has received the import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India said in a regulatory filing.

Download all types of Clinical Trial Forms

The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsules in India, subject to the receipt of related statutory approvals and licenses, it added.

Selumetinib 10 mg & 25 mg capsules are indicated for treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 and who have symptomatic, inoperable plexiform neurofibromas, it added.

DCGI nod to BDR Pharma for drug to treat various infections

DCGI approves Clinical Trial of MESOCEL therapy to treat COVID

Sputnik Single Dose Vaccine gets DCGI nod for Phase-III trials in India

DCGI grants EUA to Truenat for Nipah virus tests in India

DCGI grants EUA to Hetero’s Biosimilar Version of Tocilizumab

DCGI gives nod for Vaccine’s phase-II/III trials on kids aged between 5 and 18

AIIMS to have Satellite Brain Bank to boost research in Neurosciences

Pharma industry urges NPPA to extend revised ceiling of Heparin Inj

Medical Devices registration will benefit industry: DCGI

4,180 Tablets including Tramadol seized at Airport

One caught with Buprenorphine Inj awarded 10 years in jail

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner